Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Ministry of Health Flags Off Critical Human Immunodeficiency Virus (HIV) Commodities at Mission for Essential Drugs and Supplies (MEDS) ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...